ARTIDIS announces publication demonstrating the nanomechanical signature of response to low-dose radiotherapy followed by CAR T cell therapy in solid tumors.
November 08, 2024 08:00 ET
|
Artidis AG
BASEL, Nov. 8, 2024 — ARTIDIS, a clinical-stage health technology company developing the first clinically integrated nanomechanical platform for tissue analytics, today announced a peer-reviewed...
The Institute for Value-Based Medicine® from The American Journal of Managed Care® hosts “Cardiac Care in a Value-Based World” event in Phoenix
October 21, 2024 09:00 ET
|
The American Journal of Managed Care
CRANBURY, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, is pleased to...
Reducing Handoff Communication Failures and Inequities in Healthcare
August 22, 2024 12:25 ET
|
The Joint Commission
OAKBROOK TERRACE, Illinois, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inspiring studies related to two common sources of adverse events in healthcare – handoff communication failures, and bias and...
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
July 11, 2024 12:00 ET
|
Revolution Medicines, Inc.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in...
Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors
March 21, 2024 07:00 ET
|
Cancer Focus Fund; Eisbach Bio GmbH
Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
June 20, 2023 07:00 ET
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma First-in-human Phase 1 study of NY-ESO-1...
MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
October 03, 2022 09:05 ET
|
ARTIDIS AG
HOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD...
Houston Dash join Dynamo, MD Anderson in Making Cancer History
February 19, 2020 12:00 ET
|
Houston Dynamo
HOUSTON, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal: end cancer....
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
July 22, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22,...
Summit Medical Group to Implement Altura’s Novel HCP Studies™ Mobile Platform to Support Expanding Patient Access to Clinical Studies
June 13, 2018 08:05 ET
|
Altura
MISSION VIEJO, Calif. and BERKELEY HEIGHTS, N.J., June 13, 2018 (GLOBE NEWSWIRE) -- Altura, the pioneer in expanding participation in health-related studies by streamlining connections between...